Key Takeaways
- KOMO Biosciences has granted Syngenta a Research Evaluation License to assess its proprietary KOMbine™ platform for precision genome modification.
- The collaboration focuses on evaluating non-viral, integrase-based technology for the controlled introduction of genetic programs into maize (Zea mays).
- The KOMbine™ platform aims to overcome limitations in current genetic engineering by avoiding viral delivery and nuclease-induced DNA breaks.
- Syngenta will utilize the technology to explore advanced crop trait development, targeting improvements in stress tolerance and yield stability.
- KOMO Biosciences designed its platform to support the coordinated expression of multiple genes with long-term stability across generations.
KOMO Biosciences Licenses KOMbine™ Platform to Syngenta
KOMO Biosciences, a developer of non-viral targeted insertion technologies, has announced a strategic agreement with Syngenta. Under the terms of the Research Evaluation License, Syngenta, a global leader in agricultural innovation, will assess the capabilities of the KOMO Biosciences KOMbine™ platform. The evaluation is specifically focused on precision genome engineering within maize.
The research agreement allows Syngenta to test integrase-based genome engineering for the predictable introduction of genetic programs. This early-stage study is intended to determine how precise genomic integration can facilitate the development of advanced agricultural traits.
Addressing Engineering Constraints
A primary objective of the KOMO Biosciences platform is to solve common hurdles in genetic engineering, such as the difficulty of introducing large or complex genetic payloads into specific genomic locations. Unlike traditional methods, this technology does not rely on viral delivery systems or the induction of DNA breaks via nucleases.
This capability is increasingly relevant as modern agricultural traits require the coordinated expression of multiple genes. By providing a site-specific, programmable approach, KOMO Biosciences aims to ensure that these genetic programs remain stable and perform consistently over multiple plant generations.
Strategic Importance of KOMO Biosciences in Agriculture
Maize is a critical global crop, and its continued improvement depends on precise genomic control to manage traits like resource efficiency and stress tolerance. The partnership reflects an industry shift toward more sophisticated genome installation and control rather than simple single-gene editing.
“This evaluation reflects a broader shift in how genome engineering is evolving,” said Jennifer Manning, Founder and CEO of KOMO Biosciences. “As biological systems become more complex, the question is no longer just whether a gene can be edited, but whether genetic programs can be reliably installed and controlled.”
Syngenta R&D Integration with KOMO Biosciences
Syngenta Seeds intends to combine its expertise in plant genetics and trait introgression with the technical infrastructure provided by KOMO Biosciences. The goal is to accelerate the delivery of precise solutions to farmers globally through improved seed technology.
“At Syngenta, we’re energized by our collaboration with KOMO Biosciences,” stated Trevor Hohls, Global Head of R&D at Syngenta Seeds. “By combining our deep expertise in plant genetics and trait introgression with KOMO’s cutting-edge technology, we can accelerate our commitment to bring more precise solutions to farmers around the world.”
